Daniel H. Johnson

2.9k total citations
39 papers, 1.6k citations indexed

About

Daniel H. Johnson is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Daniel H. Johnson has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Daniel H. Johnson's work include Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (7 papers) and CAR-T cell therapy research (6 papers). Daniel H. Johnson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (7 papers) and CAR-T cell therapy research (6 papers). Daniel H. Johnson collaborates with scholars based in United States, Egypt and Sweden. Daniel H. Johnson's co-authors include Steven Henikoff, Thomas D. Dreesen, Adi Diab, Van Anh Trinh, María E. Suarez‐Almazor, Chrystia M. Zobniw, Houssein Safa, Noha Abdel‐Wahab, Heather Lin and Marc Uemura and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Daniel H. Johnson

38 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel H. Johnson United States	18	883	365	253	192	174	39	1.6k
Shuren Zhang China	20	637 0.7×	554 1.5×	453 1.8×	141 0.7×	209 1.2×	52	1.9k
Qiao Li China	24	491 0.6×	974 2.7×	429 1.7×	164 0.9×	83 0.5×	100	2.0k
Toshihisa Hamada Japan	23	177 0.2×	412 1.1×	269 1.1×	231 1.2×	97 0.6×	137	1.7k
Yi Xie China	29	400 0.5×	1.3k 3.5×	233 0.9×	181 0.9×	227 1.3×	109	2.3k
Hongmei Song China	20	156 0.2×	565 1.5×	279 1.1×	111 0.6×	133 0.8×	151	1.7k
Susan H. Hsu United States	24	170 0.2×	272 0.7×	541 2.1×	226 1.2×	268 1.5×	56	2.0k
Yannick Arlot‐Bonnemains France	24	359 0.4×	1.0k 2.8×	78 0.3×	49 0.3×	101 0.6×	62	1.7k
Zhe Yu China	22	123 0.1×	694 1.9×	167 0.7×	213 1.1×	168 1.0×	85	1.4k
Ryan R. Davis United States	24	332 0.4×	515 1.4×	136 0.5×	210 1.1×	190 1.1×	51	1.4k
Attila Kumánovics United States	19	75 0.1×	413 1.1×	730 2.9×	125 0.7×	225 1.3×	49	1.5k

Countries citing papers authored by Daniel H. Johnson

Since Specialization

Citations

This map shows the geographic impact of Daniel H. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Johnson more than expected).

Fields of papers citing papers by Daniel H. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Johnson. The network helps show where Daniel H. Johnson may publish in the future.

Co-authorship network of co-authors of Daniel H. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Johnson. A scholar is included among the top collaborators of Daniel H. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Johnson. Daniel H. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, Daniel H., Rodabe N. Amaria, Isabella Claudia Glitza, et al.. (2024). Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.. Journal of Clinical Oncology. 42(16_suppl). 9553–9553. 8 indexed citations

Eggermont, Alexander M.M., Paolo A. Ascierto, Nikhil I. Khushalani, et al.. (2022). PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence. Future Oncology. 18(8). 903–913. 8 indexed citations

Diab, Adi, Noha Abdel‐Wahab, Daniel H. Johnson, et al.. (2021). 72P Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Annals of Oncology. 32. S1403–S1403. 1 indexed citations

Johnson, Daniel H., Anisha B. Patel, Marc Uemura, et al.. (2019). IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunology Research. 7(6). 860–865. 91 indexed citations

Abdel‐Wahab, Noha, Houssein Safa, Ala Abudayyeh, et al.. (2019). Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. Journal for ImmunoTherapy of Cancer. 7(1). 106–106. 187 indexed citations

Safa, Houssein, Daniel H. Johnson, Van Anh Trinh, et al.. (2019). Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. Journal for ImmunoTherapy of Cancer. 7(1). 319–319. 194 indexed citations

Curry, Jonathan L., Alexandre Reuben, Robert Szczepaniak‐Sloane, et al.. (2019). Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14⁺ and CD16⁺ monocytes driving an innate immune response. Journal of Cutaneous Pathology. 46(9). 627–636. 32 indexed citations

Tetzlaff, Michael T., Richard R. Jahan‐Tigh, Adi Diab, et al.. (2018). Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions. Journal of Cutaneous Pathology. 45(10). 764–773. 32 indexed citations

Wang, Yinghong, Hamzah Abu‐Sbeih, Emily Mao, et al.. (2018). Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory Bowel Diseases. 24(8). 1695–1705. 178 indexed citations

10.

Abu‐Sbeih, Hamzah, Tenglong Tang, Daniel H. Johnson, Adi Diab, & Yinghong Wang. (2018). Outcomes of immune-checkpoint inhibitor induced organ toxicities.. Journal of Clinical Oncology. 36(15_suppl). 10063–10063. 1 indexed citations

11.

Kim, Sang Taek, Jean Tayar, Van Anh Trinh, et al.. (2017). Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases. 76(12). 2061–2064. 127 indexed citations

12.

Leger, Paul, Daniel H. Johnson, Gregory K. Robbins, et al.. (2014). Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. Journal of NeuroVirology. 20(3). 304–308. 13 indexed citations

13.

Moore, Carrie, Anurag Verma, Sarah A. Pendergrass, et al.. (2014). Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infectious Diseases. 2(1). ofu113–ofu113. 33 indexed citations

14.

Rutherfurd‐Markwick, Kay, Daniel H. Johnson, Martin L. Cross, & Harsharnjit S. Gill. (2005). Modified milk powder supplemented with immunostimulating whey protein concentrate (IMUCARE) enhances immune function in mice. Nutrition Research. 25(2). 197–208. 13 indexed citations

15.

Sandler, Alan B., G. R. Blumenschein, Jaewon J. Lee, et al.. (2004). Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 2000–2000. 4 indexed citations

16.

Rada, Pedro, Daniel H. Johnson, M. Lewis, & Bartley G. Hoebel. (2004). In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal. Pharmacology Biochemistry and Behavior. 79(4). 599–605. 50 indexed citations

17.

Johnson, Daniel H., Anders Svensson, Jörgen A. Engel, & Bo Söderpalm. (1995). Induction but not expression of behavioural sensitization to nicotine in the rat is dependent on glucocorticoids. European Journal of Pharmacology. 276(1-2). 155–164. 43 indexed citations

18.

Johnson, Daniel H., et al.. (1995). Subchronic intermittent nicotine treatment enhances ethanol-induced locomotor stimulation and dopamine turnover in mice. Behavioural Pharmacology. 6(2). 203???207–203???207. 32 indexed citations

19.

Johnson, Daniel H., et al.. (1993). SENSITIZATION TO NICOTINE ENHANCES ETHANOL PREFERENCE IN RATS AND ETHANOLINDUCED LOCOMOTOR ACTIVITY IN MICE. Behavioural Pharmacology. 4(4). 461–461. 1 indexed citations

20.

Johnson, Daniel H., Jan‐Erik Edström, Jean B. Burnett, & Thomas B. Friedman. (1987). Cloning of a Drosophila melanogaster adenine phosphoribosyltransferase structural gene and deduced amino acid sequence of the enzyme. Gene. 59(1). 77–86. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact